Straits Times Index
3,323.20 -6.89 (-0.21%) S&P 500
5,306.04 +1.32 (+0.02%) Dow
38,852.86 -216.74 (-0.55%) Nasdaq
17,019.88 +99.08 (+0.59%) Bitcoin USD
67,851.10 -608.24 (-0.89%) CMC Crypto 200
1,463.96 -20.73 (-1.40%)
DYN Jan 2025 25.000 put
| Previous close | 2.3000 |
| Open | 2.7000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 25.00 |
| Expiry date | 2025-01-17 |
| Day's range | 2.3000 - 2.7000 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
GlobeNewswireDyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
WALTHAM, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the closing of its previously announced underwritten public offering of 12,075,000 shares of its common stock at a public offering price of $31.00 per share, which includes 1,575,000 shares issued upon the exercise in full by the underwriters
- GlobeNewswire
Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock
WALTHAM, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the pricing of an underwritten public offering of 10,500,000 shares of its common stock at a public offering price of $31.00 per share. The gross proceeds to Dyne from the offering, before deducting underwriting discounts and commissions and
ZacksDyne (DYN) Soars 28% on New Data From Muscle Disease Studies
Dyne (DYN) gains 28% after reporting positive new data from two separate ongoing mid to late-stage studies evaluating DYNE-101 and DYNE-251 for different muscle disease indications.
